| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
EBV lytic cycle inducer-1 targets the latent Epstein-Barr virus (EBV) infection by inducing the viral lytic cycle. EBV establishes a latent infection in B cells and epithelial cells, which is associated with various malignancies including Burkitt's lymphoma, nasopharyngeal carcinoma, and gastric cancer. By promoting viral reactivation from latency, the compound makes the virus susceptible to antiviral agents and immune clearance. The compound is an iron chelate-like compound that synergizes with HDAC inhibitors to induce the EBV lytic cycle.
|
|---|---|
| ln Vitro |
In a cell line-dependent way, Dp44mT (compound C7) (0-80 μM, 48 h) triggers the lytic cycle; its induction ability in AGS-BX1 cells is higher than that in AGX cells [1]. In a time-dependent manner, the lytic cycle is induced by Dp44mT (10 μM, 0-72 h) [1]. Inducing the EBV lytic cycle, Dp44mT (1.25-2.5 μM, 24 h) works in concert with SAHA and Romidespin, two HDAC inhibitors [1]. Dp44mT (20 μM, 48 h) induces the ERK-autophage axis, which reactivates the EBV lytic cycle [2].
In vitro studies demonstrate that EBV lytic cycle inducer-1 (compound C7) induces the lytic cycle of EBV in a cell-line-dependent manner, with a higher inductive capacity on AGS-BX1 cells compared to AGX cells, in the concentration range of 0-80 μM for 48 hours. The compound synergizes with the HDAC inhibitors Romidepsin and SAHA to induce the EBV lytic cycle. The compound is an iron chelate-like compound that promotes viral reactivation. |
| ln Vivo |
No detailed in vivo activity data has been published for EBV lytic cycle inducer-1. The compound has been primarily characterized in vitro as a research tool for studying EBV reactivation. Its ability to induce the EBV lytic cycle suggests that it could have potential for in vivo applications in treating EBV-associated malignancies by making latently infected cells susceptible to antiviral therapy. Further studies would be needed to evaluate its efficacy in animal models.
|
| Enzyme Assay |
The EBV lytic cycle-inducing activity of EBV lytic cycle inducer-1 can be assessed using EBV-infected cell lines. In a typical assay, EBV-positive cell lines (such as AGS-BX1 or AGX cells) are treated with varying concentrations of EBV lytic cycle inducer-1 (0-80 μM) for 48 hours. EBV lytic cycle induction is assessed by measuring the expression of lytic cycle genes (such as BZLF1 and BMRF1) by qPCR or by Western blotting. The compound's ability to synergize with HDAC inhibitors can be assessed by combining the compound with Romidepsin or SAHA.
|
| Cell Assay |
Immunofluorescence[1]
Cell Types: AGS AGS-BX1 Tested Concentrations: 10 μM Incubation Duration: 24 h, 48 h, 72 h Experimental Results: Resulted the expression of IE proteins Zta, Rta, and early EBV lytic protein BMRF1 peaking at 24h post treatment. Immunofluorescence[1] Cell Types: AGS-BX1 Tested Concentrations: 1.25 μM, 2.5 μM Incubation Duration: 24 h Experimental Results: Synergistically induced the expression of the viral IE protein Zta could together with 2.5 μM of SAHA and 2.5 nM of Rmidepsin. Immunofluorescence[2] Cell Types: HA cells Tested Concentrations: 20 μM Incubation Duration: 24 h Experimental Results: A Dramatically lower expression of Zta was observed in cells treated with the iron-precomplexed C7 when compared to cells treated with C7 with 41% higher. Cell Proliferation Assay[1] Cell Types: AGS, AGS-BX1 Tested Concentrations: 0 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, 80 μM Incubation Duration: 48 h Experimental Results: Displayed Dramatically higher toxicity to the EBV-positive cell line AGS-BX1 than the EBV-negative counterpart. The cellular activity of EBV lytic cycle inducer-1 is assessed using EBV-positive cell lines. Cells are treated with varying concentrations of the compound (0-80 μM) for 48 hours. EBV lytic cycle induction is assessed by measuring the expression of lytic cycle genes (such as BZLF1 and BMRF1) by qPCR or by Western blotting. Viral particle production can be assessed by measuring viral DNA in the culture supernatant or by infectivity assays. The compound's iron chelating activity can be assessed using iron chelation assays. |
| Animal Protocol |
No detailed in vivo animal model data has been published for EBV lytic cycle inducer-1. The compound has been primarily characterized in vitro as a research tool for studying EBV reactivation. Future studies may involve the use of mouse models of EBV-associated malignancies to assess the in vivo efficacy of EBV lytic cycle inducer-1, either alone or in combination with HDAC inhibitors or antiviral agents.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data has been published for EBV lytic cycle inducer-1. The compound has a molecular weight of 318.17 and a molecular formula of C14H12BrN3O. It has a purity of ≥98%. Further studies would be needed to characterize its absorption, distribution, metabolism, and excretion properties, including oral bioavailability, plasma protein binding, clearance, and half-life.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data has been published for EBV lytic cycle inducer-1. As an iron chelate-like compound, it may have effects on iron metabolism and cellular redox balance. Comprehensive toxicology studies would be required to evaluate its safety profile for potential therapeutic development. The compound is intended for research use only.
|
| References |
|
| Additional Infomation |
EBV lytic cycle inducer-1 (Dp44mT, compound C7, CAS# 394668-43-0) is an iron chelate-like compound that induces the lytic cycle of Epstein-Barr virus (EBV). It induces the lytic cycle in a cell-line-dependent manner (0-80 μM, 48 hours) and synergizes with HDAC inhibitors Romidepsin and SAHA. The compound promotes viral reactivation from latency, making virus-infected cells susceptible to antiviral therapy. The molecular formula is C14H12BrN3O and molecular weight is 318.17. The compound is a research tool for studying EBV reactivation and developing therapies for EBV-associated malignancies.
|
| Molecular Formula |
C14H12BRN3O
|
|---|---|
| Molecular Weight |
318.168581962585
|
| Exact Mass |
317.016
|
| CAS # |
394668-43-0
|
| PubChem CID |
5341487
|
| Appearance |
White to off-white solid powder
|
| LogP |
3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
346
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C/C(=N\NC(=O)C1=CC(=CC=C1)Br)/C2=CC=CC=N2
|
| InChi Key |
GZJPBATWGXWPLE-LICLKQGHSA-N
|
| InChi Code |
InChI=1S/C14H12BrN3O/c1-10(13-7-2-3-8-16-13)17-18-14(19)11-5-4-6-12(15)9-11/h2-9H,1H3,(H,18,19)/b17-10+
|
| Chemical Name |
3-bromo-N-[(E)-1-pyridin-2-ylethylideneamino]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~39.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.56 mg/mL (1.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.6 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.56 mg/mL (1.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.6 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.56 mg/mL (1.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1430 mL | 15.7149 mL | 31.4297 mL | |
| 5 mM | 0.6286 mL | 3.1430 mL | 6.2859 mL | |
| 10 mM | 0.3143 mL | 1.5715 mL | 3.1430 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
